| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8662318 | International Journal of Cardiology | 2018 | 21 Pages |
Abstract
Interruption of study drug was frequent in patients with AF and was associated with a substantial risk of major cardiac and cerebrovascular events over the ensuing 30â¯days. This risk was particularly high in patients who interrupted as a result of an adverse event; these patients deserve close monitoring and resumption of anticoagulation as soon as it is safe to do so.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ilaria Cavallari, Christian T. Ruff, Francesco Nordio, Naveen Deenadayalu, Minggao Shi, Hans Lanz, Howard Rutman, Michele F. Mercuri, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano,